[Thrombocytopenia in a patient on peritoneal dialysis]

Area of Science:

• Pharmacology
• Nephrology
• Infectious Diseases

Background:

• Adverse drug reactions (ADRs) affect up to 6% of hospitalized patients, increasing morbidity and mortality.
• Beta-lactams and sulfonamides are frequently linked to hypersensitivity reactions.
• Vancomycin, a glycopeptide antibiotic, is crucial for treating Staph infections, especially with rising antibiotic resistance.

Observation:

• Vancomycin is a primary treatment for staphylococcal infections in nephrology patients, including those with central venous catheters for hemodialysis and peritoneal dialysis peritonitis.
• Vancomycin use is increasing due to bacterial resistance to traditional antibiotics like beta-lactams.
• Nephrology units frequently utilize vancomycin for staphylococcal infections associated with dialysis access and peritonitis.

Findings:

• Vancomycin toxicity encompasses "red man syndrome", ototoxicity, and hematological toxicity.
• The most frequent hematological toxicity observed is mild neutropenia.
• Less common hematological adverse effects include leukocytosis, eosinophilia, agranulocytosis, and thrombocytopenia.

Implications:

• Understanding vancomycin's toxicity profile is critical for safe patient management, particularly in nephrology.
• Monitoring for hematological changes is essential during vancomycin therapy.
• The rise in antibiotic resistance necessitates careful consideration of vancomycin's benefits against its potential toxicities.